

**Registered Office:**

Plot No. PF21 & PF-22/A, Charal Industrial Estate,  
Sanand GIDC-II, Sanand,  
Ahmedabad- 382110, Gujarat.

**CIN.: L24230GJ2015PLC085451**

**Date: September 05, 2025**

**To,**  
**Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex  
Bandra East, Mumbai-400051

Respected Sir/Ma'am,

**Sub: Submission of Notice of 10<sup>th</sup> Annual General Meeting.**

**Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)**

We wish to inform you that the 10<sup>th</sup> Annual General Meeting of the Company on Monday, September 29, 2025 at 12:00 P.M. (Noon) (IST) through Video Conferencing (VC) or Other Audio Visual Means (OVAM) in compliance with the applicable circulars of Ministry of Corporate Affairs (MCA) and SEBI to transact the businesses mentioned in the Notice of 10<sup>th</sup> Annual General Meeting.

We have attached herewith the Notice of 10<sup>th</sup> Annual General Meeting of our Company for kind perusal of Stakeholders.

We would further like to inform that the Company has fixed Monday, September 22, 2025 as the cut-off date for ascertaining the names of the members holding shares in dematerialised form, who will be entitled to cast their votes electronically in respect of the businesses to be transacted as per the Notice of the AGM and to attend the AGM.

You are requested to take the same on your records.

**For, Sotac Pharmaceuticals Limited**

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**

**Place: Ahmedabad**

**Encl: A/a-**

## NOTICE OF 10<sup>TH</sup> ANNUAL GENERAL MEETING

**NOTICE** is hereby given that the Tenth (10<sup>th</sup>) Annual General Meeting (AGM) of the Members of **Sotac Pharmaceuticals Limited** ("the Company") will be held on Monday, September 29, 2025 at 12:00 Noon IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following businesses:

### ORDINARY BUSINESSES:

#### 1. Adoption of Audited Financial Statements:

To receive, consider and adopt;

(a) The Audited Standalone Financial Statement of the Company for the Financial Year ended on March 31, 2025 and the report of the Board of Directors and Auditors thereon; and

(b) The Audited Consolidated Financial Statement of the Company for the Financial Year ended on March 31, 2025 and the report of Auditors thereon.

In this regard, to consider and if thought fit, to pass, with or without modification(s), the following resolutions as an **Ordinary Resolution**;

(a) **"RESOLVED THAT** the Audited Standalone financial statement of the Company for the financial year ended on March 31, 2025 and the reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby considered and adopted."

(b) **"RESOLVED THAT** the Audited consolidated financial statement of the Company for the financial year ended on March 31, 2025 and the report of Auditors thereon, as circulated to the members, be and are hereby considered and adopted."

#### 2. To appoint a director in place of Mr. Dineshkumar Babulal Gelot (DIN: 07252132), who retires by rotation and being eligible, offers himself for re-appointment:

To appoint Mr. Dineshkumar Babulal Gelot (DIN: 07252132), Whole Time Director, who retires by rotation and being eligible, offers himself for re-appointment;

**Explanation:** Based on the terms of appointment, Executive Directors and the Non-Executive Directors (other than Independent Directors) are subject to retirement by rotation. Mr. Dineshkumar Babulal Gelot (DIN: 07252132), Whole Time Director who has been on the Board of the Company since December 18, 2015 and is the longest serving member on the Board, is liable to retire at this AGM, being eligible, has offered himself for re-appointment. Based on the performance evaluation and the recommendation of the Nomination and Remuneration Committee, the Board recommends his re-appointment.

Therefore, shareholders are requested to consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

**"RESOLVED THAT**, pursuant to the provisions of Section 152 and other applicable provisions and the Rules framed thereunder, if any, of the Companies Act, 2013, (including any statutory modification(s) or re-enactment thereof for the time being in force), the approval of the shareholders of the Company be and is hereby accorded for the re-appointment of Mr. Dineshkumar Babulal Gelot (DIN: 07252132), Whole Time Director, who retires by rotation, and being eligible, has offered himself for reappointment."

**3. To declare final dividend of Rs. 0.10/- (Ten paise only) per Equity share of face value Rs.10/- each (i.e. 1% of face value) for the financial year ended on March 31, 2025:**

The Board of Directors is pleased to recommend a Final Dividend of Rs. 0.10/- (Ten Paise only) per equity share having a face value of Rs. 10/- each, i.e., 1.00% of face value, for the financial year ended March 31, 2025.

Therefore, shareholders are requested to consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** a Final Dividend of Rs. 0.10 (Ten Paise only) per equity share for 1,10,50,000 equity shares of face value Rs. 10/- each fully paid-up of the Company (i.e., 1% of face value), as recommended by the Board of Directors, be and is hereby declared for the financial year ended on March 31, 2025 and the same be paid out of the profits of the Company.”

**SPECIAL BUSINESSES:**

**4. To ratify the remuneration payable to M/s. Suthar Hareesh & Associates, Cost Accountants (FRN.: 002124) Cost Auditor of the Company for the Financial Year ended on March 31, 2026:**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to the provisions of Section 148(3) and any other applicable provision(s), if any, of the Companies Act, 2013, read with the Rule 14 of Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the consent of the members be and is hereby accorded to ratify the remuneration of Rs. 50,000/- (Rupees Fifty Thousand Only) plus applicable taxes and reimbursement of out of pocket expenses payable to M/s. Suthar Hareesh & Associates, Cost Accountants (FRN.: 002124), Ahmedabad, appointed by the Board of Directors of the Company in their meeting held on August 30, 2025 as a Cost Auditor of the Company, based on the recommendations of the Audit Committee, to conduct the audit of the cost records of the Company for the financial year ended on March 31, 2026.

**RESOLVED FURTHER THAT** the Board of Directors of the Company including its committee of Directors thereof, be and are hereby severally authorized to do all acts, deeds, matters and take all such steps as may be necessary, proper or expedient to give effect to this resolution including certifying and filing of necessary forms and documents with the Registrar of Companies.”

**5. Ratification of Remuneration payable to Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252), Chairman and Managing Director of the Company for his remaining term:**

To consider, and, if thought fit to pass, with or without modification(s), the following resolution as a **Special Resolution**:

**“RESOLVED THAT** pursuant to the provisions of section 196, 197, 198, 203 and other applicable provisions of the companies act, 2013, and schedule V of the act read with companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the ministry of corporate affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as “the Board”), the approval of the Members of the Company be and is hereby accorded for Ratification of remuneration excluding perquisites (hereinafter referred to as “remuneration”) payable to Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252), Chairman and Managing Director of the company as set out in the explanatory statement attached hereto, for his remaining term until revised further with all other terms and conditions of his appointment remaining unchanged, and in accordance with the provisions of the Act and in the best interest of the Company.

**RESOLVED FURTHER THAT** in the event of any statutory amendment/ modification of Schedule V, the Board of Directors or a Committee thereof be and is hereby authorized to alter, vary or increase the remuneration of the appointee within such prescribed limits of Schedule V of the Companies Act, 2013.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to undertake all such steps, as may be deemed necessary in this matter.

**RESOLVED FURTHER THAT** the Executive Directors or the Company Secretary of the Company, be and are hereby severally authorized to file the said resolution with the Registrar of Companies, Ahmedabad, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution.”

**6. Ratification of Remuneration payable to Mr. Dineshkumar Babulal Gelot (DIN: 07252132), Whole-time director of the Company for his remaining term:**

To consider, and, if thought fit to pass, with or without modification(s), the following resolution as a **Special Resolution**:

**“RESOLVED THAT** pursuant to the provisions of section 196, 197, 198, 203 and other applicable provisions of the companies act, 2013, and schedule V of the act read with companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the ministry of corporate affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as “the Board”), the approval of the Members of the Company be and is hereby accorded for Ratification of remuneration excluding perquisites (hereinafter referred to as “remuneration”) payable to Mr. Dineshkumar Babulal Gelot (DIN: 07252132), Whole-time director of the company as set out in the explanatory statement attached hereto, for his remaining term until revised further with all other terms and conditions of his appointment remaining unchanged, and in accordance with the provisions of the Act and in the best interest of the Company.

**RESOLVED FURTHER THAT** in the event of any statutory amendment/ modification of Schedule V, the Board of Directors or a Committee thereof be and is hereby authorized to alter, vary or increase the remuneration of the appointee within such prescribed limits of Schedule V of the Companies Act, 2013.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to undertake all such steps, as may be deemed necessary in this matter.

**RESOLVED FURTHER THAT** the Executive Directors or the Company Secretary of the Company, be and are hereby severally authorized to file the said resolution with the Registrar of Companies, Ahmedabad, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution.”

**7. Revision in Remuneration payable to Mr. Vishalkumar Patel (DIN: 07252191), Executive Director of the Company:**

To consider, and, if thought fit to pass, with or without modification(s), the following resolution as a **Special Resolution**:

**“RESOLVED THAT** pursuant to the provisions of section 196, 197, 198 and other applicable provisions of the companies act, 2013, and schedule V of the act read with companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the ministry of corporate affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as “the Board”), the approval of the Members of the Company be and is hereby accorded for revision in remuneration excluding perquisites (hereinafter referred to as “remuneration”) payable to Mr. Vishalkumar Patel (DIN: 07252191), Executive Director of the company as set out in the explanatory statement attached hereto, for term of three (3) years until revised further with all other terms and conditions of his appointment remaining unchanged, and in accordance with the provisions of the Act and in the best interest of the Company.

**RESOLVED FURTHER THAT** in the event of any statutory amendment/ modification of Schedule V, the Board of Directors or a Committee thereof be and is hereby authorized to alter, vary or increase the remuneration of the appointee within such prescribed limits of Schedule V of the Companies Act, 2013.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to undertake all such steps, as may be deemed necessary in this matter.

**RESOLVED FURTHER THAT** the Executive Directors or the Company Secretary of the Company, be and are hereby severally authorized to file the said resolution with the Registrar of Companies, Ahmedabad, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution.”

**8. Revision in Remuneration payable to Mr. Chetankumar Bachubhai Patel (DIN: 07252116), Executive Director of the Company:**

To consider, and, if thought fit to pass, with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of section 196, 197, 198 and other applicable provisions of the companies act, 2013, and schedule V of the act read with companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable rules, regulations issued by the ministry of corporate affairs in this regard including any statutory amendments, modifications or re-enactment thereof and all other statutory approvals, as may be required and on recommendation of Nomination and Remuneration Committee and pursuant to approval of the Board of Directors (hereinafter referred to as “the Board”), the approval of the Members of the Company be and is hereby accorded for revision in remuneration excluding perquisites (hereinafter referred to as “remuneration”) payable to Mr. Chetankumar Bachubhai Patel (DIN: 07252116), Executive Director of the company as set out in the explanatory statement attached hereto, for term of three (3) years until revised further with all other terms and conditions of his appointment remaining unchanged, and in accordance with the provisions of the Act and in the best interest of the Company.

**RESOLVED FURTHER THAT** in the event of any statutory amendment/ modification of Schedule V, the Board of Directors or a Committee thereof be and is hereby authorized to alter, vary or increase the remuneration of the appointee within such prescribed limits of Schedule V of the Companies Act, 2013.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this Resolution, the Board of Directors (or any Committee thereof) be and is hereby authorized to undertake all acts, deeds and execute all documents and pass relevant resolutions for the purpose of giving effect to this resolution, including modification and amendment of any revisions, thereof and to undertake all such steps, as may be deemed necessary in this matter.

**RESOLVED FURTHER THAT** the Executive Directors or the Company Secretary of the Company, be and are hereby severally authorized to file the said resolution with the Registrar of Companies, Ahmedabad, and to do all such acts, deeds and things as may be necessary, expedient and incidental thereto to give effect to the above resolution.”

**9. To approve the appointment of Ms. Dimpalben Dhebarbhai Patel (DIN:11122579) as a Non-Executive Independent Director of the Company for a period of 5 (five) years:**

To consider, and, if thought fit to pass, with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152 and any other applicable provisions of the Companies Act, 2013 (“Act”) and the rules made there under read with Schedule IV of the Act, and applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”)(including any statutory modification or re-enactment thereof for the time being in force), and on the approval and recommendation of the Nomination and Remuneration Committee and that of the Board of Directors, Ms. Dimpalben Dhebarbhai Patel (DIN: 11122579), who was appointed as an Additional Director in the capacity of an Non-Executive Independent Director w.e.f. May 24, 2025, who in terms of Section 161 of the Companies Act, 2013 holds office till ensuing

Annual General Meeting, who meets the criteria for independence under Section 149(6) of the Act and the Rules made thereunder and in respect of whom the Company has received a notice in writing under Section 160(1) of the Act proposing her candidature for the office of Director on the Board of Directors of the Company, be and is hereby appointed as a Non-Executive Independent Director of the Company for a period of five (5) years till May 23, 2030 and that shall not be liable to retire by rotation.

**RESOLVED FURTHER THAT** the Executive Director or the Company Secretary be and are hereby severally authorized to settle and question, difficulty or doubt, that may arise in giving effect to this resolution and to do all such acts, deeds and things as may be necessary order, proper or expedient for the purpose of giving effect to this resolution.”

**10. To Approve the Material related party transaction(s) proposed to be entered into by the Company during the FY 2025-26 with Sotac Healthcare Private Limited (“Subsidiary company”):**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to Section 188 and other applicable provisions if any of the Companies Act, 2013 Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and applicable provision of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as “Listing Regulations”) and any other applicable provisions, including any amendment, modification, variation or re-enactment thereof and the Company’s Policy on Related Party Transactions and based on the recommendation of the Audit Committee and the Board of Directors, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the “Board” which term shall be deemed to include any committee(s) constituted/to be constituted by the Board, from time to time, to exercise its powers conferred by this resolution), for entering into, continuing, and/or carrying out existing and/or new transactions, contracts, or arrangements (whether individual transaction or transactions taken together or series of transactions or otherwise) with Sotac Healthcare Private Limited, as detailed in the Explanatory Statement, relating to Sale, purchase, supply of any goods or materials, or provision/availing of services or such other transactions, on such terms and conditions as may be mutually agreed, for the financial year 2025–26, for an aggregate value not exceeding Rs. 25 Crores (Rupees Twenty-Five Crores Only)

**RESOLVED FURTHER THAT** the Board of Directors of the company (including a Committee thereof) be and is hereby authorized to negotiate and finalize other terms and conditions and to do all such acts deeds matters and things and to execute or to authorize any person to execute all such documents instruments and writings as may be considered necessary relevant usual customary and/or expedient to give effect to this resolution.”

**11. To Approve the Material related party transaction(s) proposed to be entered into by the Company during the FY 2025-26 with Sotac Lifesciences Private Limited (“Subsidiary company”):**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to Section 188 and other applicable provisions if any of the Companies Act, 2013 Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and applicable provision of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as “Listing Regulations”) and any other applicable provisions, including any amendment, modification, variation or re-enactment thereof and the Company’s Policy on Related Party Transactions and based on the recommendation of the Audit Committee and the Board of Directors, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the “Board” which term shall be deemed to include any committee(s) constituted/to be constituted by the Board, from time to time, to exercise its powers conferred by this resolution), for entering into, continuing, and/or carrying out existing and/or new transactions, contracts, or arrangements (whether individual transaction or transactions taken together or series of transactions or otherwise) with Sotac Lifesciences Private Limited, as detailed in the Explanatory Statement, relating to Sale, purchase, supply of any goods or materials, or provision/availing of services or such other transactions, on such terms and conditions as may be mutually agreed, for the financial year 2025–26, for an aggregate value not exceeding Rs. 25 Crores (Rupees Twenty-Five Crores Only)



**RESOLVED FURTHER THAT** the Board of Directors of the company (including a Committee thereof) be and is hereby authorized to negotiate and finalize other terms and conditions and to do all such acts deeds matters and things and to execute or to authorize any person to execute all such documents instruments and writings as may be considered necessary relevant usual customary and/or expedient to give effect to this resolution.”

**12. To Approve the Material related party transaction(s) proposed to be entered into by the Company during the FY 2025-26 with Sotac Research Private Limited (“Wholly Owned Subsidiary company”):**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to Section 188 and other applicable provisions if any of the Companies Act, 2013 Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and applicable provision of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as “Listing Regulations”) and any other applicable provisions, including any amendment, modification, variation or re-enactment thereof and the Company’s Policy on Related Party Transactions and based on the recommendation of the Audit Committee and the Board of Directors, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the “Board” which term shall be deemed to include any committee(s) constituted/to be constituted by the Board, from time to time, to exercise its powers conferred by this resolution), for entering into, continuing, and/or carrying out existing and/or new transactions, contracts, or arrangements (whether individual transaction or transactions taken together or series of transactions or otherwise) with Sotac Research Private Limited, as detailed in the Explanatory Statement, relating to Sale, purchase, supply of any goods or materials, or provision/availing of services or such other transactions, on such terms and conditions as may be mutually agreed, for the financial year 2025–26, for an aggregate value not exceeding Rs. 25 Crores (Rupees Twenty-Five Crores Only)

**RESOLVED FURTHER THAT** the Board of Directors of the company (including a Committee thereof) be and is hereby authorized to negotiate and finalize other terms and conditions and to do all such acts deeds matters and things and to execute or to authorize any person to execute all such documents instruments and writings as may be considered necessary relevant usual customary and/or expedient to give effect to this resolution.”

**Registered office:**

Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, 382110 Gujarat, India

For and on behalf of Board of Directors  
**Sotac Pharmaceuticals Limited**  
**CIN: L24230GJ2015PLC085451**

**Place:** Ahmedabad  
**Date:** August 30, 2025

Sd/-  
**Sharadkumar Dashrathbhai Patel**  
**Chairman & Managing Director**  
**DIN: 07252252**

Sd/-  
**Dineshkumar Babulal Gelot**  
**Whole time Director**  
**DIN: 07252132**

## IMPORTANT NOTES

1. The Government of India, Ministry of Corporate Affairs has allowed conducting Annual General Meeting through Video Conferencing (VC) or Other Audio Visual Means (OAVM) and dispensed the personal presence of the members at the meeting. Accordingly, the Ministry of Corporate Affairs issued Circular No. 14/2020 dated April 08, 2020, Circular No. 17/2020 dated April 13, 2020 and Circular No. 20/2020 dated May 05, 2020 and Circular No. 02/2021 dated January 13, 2021 and Circular No. 21/2021 dated December 14, 2021 and 02/2022 dated May 05, 2022, 10/2022 dated December 28, 2022 and 09/2023 dated September 25, 2023 and latest being 09/2024 dated September 19, 2024 ("MCA Circulars") and Circular no. SEBI/HO/CFD/ CMD1/CIR/P/2020/79 dated May 12, 2020, Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, Circular No. SEBI/HO/CFD/ CMD2/CIR/P/2022/62 dated May 13, 2022, SEBI/ HO/CRD/PoD-2/P/CIR/2023/4 dated January 05, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/ CIR/2023/167 dated October 07, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 03, 2024 issued by the Securities Exchange Board of India ("SEBI Circular") prescribing the procedure and manner for conducting AGMs through VC/OAVM without the physical presence of members at a common venue. In terms of the said circulars, the 10<sup>th</sup> Annual General Meeting ("AGM") of the Members will be held through VC/OAVM on Monday, September 29, 2025, at 12:00 P.M. IST. Members can attend and participate in the AGM only through VC/OAVM. The deemed venue of the AGM proceedings shall be the Registered Office of the Company at Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Sanand, Ahmedabad, Sanand, Gujarat, 382110 India.
2. Pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations') and Secretarial Standard-2 on General Meetings, issued by The Institute of Company Secretaries of India, in respect of appointment/reappointment of directors at the 10<sup>th</sup> Annual General Meeting ('Meeting' or 'AGM') is furnished as Annexure to this Notice.
3. Pursuant to the provisions of the Act, a member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote on his/her behalf at the Meeting and a proxy need not be a member of the Company. Since this AGM is being held through VC pursuant to the MCA Circulars, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and attendance slip are not annexed hereto.
4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
5. Since the AGM will be held through VC/ OAVM, the route map of the venue of the Meeting is not annexed hereto;
6. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
7. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), the MCA Circulars & SEBI Circulars, the Company is providing facility of remote eVoting to its Members in respect of the businesses to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote eVoting system as well as venue voting on the date of the AGM will be provided by NSDL.
8. Notice calling the AGM has been sent by electronic means to those members who had registered their email addresses with the Company/Depositories. The Notice has also been uploaded on the website of the Company at [www.sotacpharma.com](http://www.sotacpharma.com) & the website of the Stock Exchange i.e. NSE Limited at <https://www.nseindia.com/> and is also made available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. [www.evoting.nsdl.com](http://www.evoting.nsdl.com).



9. Members holding shares in dematerialized mode are requested to register/update their email addresses with the relevant Depository Participants.
10. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc.,
11. Members seeking clarifications on the Annual Report are requested to send in written queries to the Company at least 7 days before the date of the meeting. This would enable the Company to compile the information and provide the replies at the Meeting.
12. To prevent fraudulent transactions, members are advised to exercise due diligence and notify the Company of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant and holdings should be verified.
13. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Act, and the Register of Contracts or Arrangements in which the directors are interested, maintained under Section 189 of the Act, will be available electronically for inspection by the members during the AGM. All documents referred to in the Notice will also be available for electronic inspection without any fee by the members from the date of circulation of this Notice up to the date of AGM, i.e. Monday, September 29, 2025 Members seeking to inspect such documents can send an email to [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com).
14. In compliance with Section 108 of the Act, read with the corresponding rules, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations"), the Company has provided a facility to its members to exercise their votes electronically through the electronic voting ("e-voting") facility provided by the NSDL. Members who have cast their votes by remote e-voting prior to the AGM may participate in the AGM but shall not be entitled to cast their votes again. The manner of voting remotely by members holding shares in dematerialized mode is provided in the instructions for evoting section which forms part of this Notice. The Board has appointed M/s. SCS & Co. LLP, Company Secretaries (M. No.: 41942, COP: 23630), as the Scrutinizer to scrutinize the e-voting in a fair and transparent manner.
15. The e-voting period commences on Friday, September 26, 2025 at 09:00 A.M. (IST) and ends on Sunday, September 28, 2025 at 05:00 P.M. (IST). During this period, members holding shares in dematerialized form, as on cut-off date, i.e. as on Monday, September 22, 2025 may cast their votes electronically. The e-voting module will be disabled by NSDL for voting thereafter. A member will not be allowed to vote again on any resolutions on which vote have already been cast.
16. There being no physical shareholders in the Company, the Register of members and share transfer books of the Company will not be closed. Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off date i.e. Monday, September 22, 2025 be entitled to avail the facility of remote e-voting as well as e-voting system on the date of the AGM. Any recipient of the Notice, who has no voting rights as on the Cut-off date, shall treat this Notice as intimation only.
17. A person who has acquired the shares and has become a member of the Company after the dispatch of the Notice of the AGM and prior to the Cut-off date i.e. Monday, September 22, 2025, shall be entitled to exercise his/her vote either electronically i.e. remote e-voting or e-voting system on the date of the AGM by following the procedure mentioned in this part.
18. Once the vote on resolutions is cast by the member, he/she shall not be allowed to change it subsequently or cast the vote again.
19. The voting rights of the members shall be in proportion to their share in the paid-up equity share capital of the Company as on the Cut-off date i.e. Monday, September 22, 2025.

**THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:**

The remote e-voting period begins on Friday, September 26, 2025 at 09:00 A.M. (IST) and ends on Sunday, September 28, 2025 at 05:00 P.M. (IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. on Monday, September 22, 2025, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Monday, September 22, 2025.

**How do I vote electronically using NSDL e-Voting system?**

*The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:*

**Step 1: Access to NSDL e-Voting system**

**A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
<b>Individual Shareholders holding securities in demat mode with NSDL.</b>	<ol style="list-style-type: none"> <li>For OTP based login you can click on <a href="https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp">https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp</a>. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>If you are not registered for IDEAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “<b>Register Online for IDEAS Portal</b>” or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>Shareholders/Members can also download NSDL Mobile App “NSDL Speede”</li> </ol>

facility by scanning the QR code mentioned below for seamless voting experience.

**NSDL Mobile App is available on**



**Individual Shareholders holding securities in demat mode with CDSL**

1. Existing users who have opted for Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <https://web.cdslindia.com/myeasi/home/login> or [www.cdslindia.com](http://www.cdslindia.com) and click on New System Myeasi.
2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.
3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website [www.cdslindia.com](http://www.cdslindia.com) and click on login & New System Myeasi Tab and then click on registration option.
4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on [www.cdslindia.com](http://www.cdslindia.com) home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

**Individual Shareholders (holding securities in demat mode) login through their depository participants**

You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL:**

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.com">evoting@nsdl.com</a> or call 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800-21-09911

**B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

**How to Log-in to NSDL e-Voting website?**

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen. *Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.*
4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
<b>a) For Members who hold shares in demat account with NSDL.</b>	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
<b>b) For Members who hold shares in demat account with CDSL.</b>	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
<b>c) For Members holding shares in Physical Form.</b>	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

**5. Password details for shareholders other than Individual shareholders are given below:**

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
- i. If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your

email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8-digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

- ii. If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

- a) Click on "**Forgot User Details/Password?**" (If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
- b) **Physical User Reset Password?** (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
- c) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.com](mailto:evoting@nsdl.com) mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
- d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

## Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

### How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

### General Guidelines for shareholders:

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to [scsandcollp@gmail.com](mailto:scsandcollp@gmail.com) with a copy marked to [evoting@nsdl.com](mailto:evoting@nsdl.com). Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request at [evoting@nsdl.com](mailto:evoting@nsdl.com).

**Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:**

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com).
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com).
3. If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
4. Alternatively, shareholder/members may send a request to [evoting@nsdl.com](mailto:evoting@nsdl.com) for procuring user id and password for e-voting by providing above mentioned documents.
5. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

**THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER: -**

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM
3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

**INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE 10<sup>th</sup> AGM THROUGH VC/OAVM ARE AS UNDER:**

1. Member will be provided with a facility to attend the 10<sup>th</sup> AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under **"Join meeting"** menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.



4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. For ease of conduct, Members who would like to ask questions may send their questions in advance at least seven (7) days before AGM mentioning their name, demat account number/folio number, email id, mobile number at [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com) and register themselves as a speaker. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM.
6. Since the AGM will be held through VC/OAVM, the Route Map is not annexed in this Notice.
7. The Scrutinizer shall, after the conclusion of voting at the AGM, unblock the votes cast through remote e-Voting and count the same, and count the votes casted during the AGM, and shall make, not later than 48 hours from the conclusion of the AGM, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same and declare the result of the voting forthwith. The Scrutinizer's decision on the validity of the votes shall be final.

The results declared along with the Scrutinizer's Report shall be placed on the Company's website <https://sotacpharma.com/> and on the website of NSDL [www.evoting.nsdl.com](http://www.evoting.nsdl.com) within two days of the passing of the Resolutions at the 10<sup>th</sup> Annual General Meeting of the Company and shall also be communicated to the Stock Exchanges where the shares of the Company are listed.

#### Information on dividend:

1. Members may note that the Board of Directors at its meeting held on May 28, 2025, has recommended a final dividend of INR 0.10/- per equity share for the financial year ended March 31, 2025. The final dividend, if approved at the AGM, will be paid on or before October 29, 2025 to those Members whose names are on the Company's Register of Members and to those whose names appear as Beneficial Owners as at the close of the business hours on Monday, September 22, 2025 as per the details to be furnished by the Depositories, viz. NSDL and CDSL for this purpose.
2. Dividends, if not encashed for a period of 7 years from the date of transfer to Unpaid Dividend Accounts of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). Further, the shares in respect of which dividend has remained unclaimed for 7 consecutive years or more from the date of transfer to unpaid dividend accounts shall also be transferred to IEPF. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline.
3. In accordance with the provisions of the Income Tax Act, 1961 as amended by and read with the provisions of the Finance Act, 2020, with effect from April 1, 2020, dividend declared and paid by the Company is taxable in the hands of its Members and the Company is required to deduct tax at source (TDS) from dividend paid to the Members at the applicable rates.
4. In general, to enable compliance with TDS requirements, Members are requested to complete and/or update their Residential Status, valid PAN linked to Aadhaar and Category as per the IT Act with their Depository Participants ("DPs") or in case shares are held in physical form, with the Company.
5. A Resident individual shareholder with PAN and who is not liable to pay income tax can submit a yearly declaration in Form No. 15G / 15H, to avail the benefit of non-deduction of tax at source by e-mail to [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com) by September 21, 2025. Shareholders are requested to note that in case their PAN is not registered, the tax will be deducted at a higher rate of 20%.
6. Non-resident shareholders [including Foreign Institutional Investors (FIIs) / Foreign Portfolio Investors (FPIs)] can avail beneficial rates under tax treaty between India and their country of tax residence, subject to providing necessary documents i.e. No Permanent Establishment and Beneficial Ownership Declaration, Tax Residency Certificate, Form 10F, any other document which may be required to avail the tax treaty benefits. For this purpose, the shareholder may submit the above documents (PDF / JPG

Format) by e-mail to [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com). The aforesaid declarations and documents need to be submitted by the shareholders September 21, 2025.

7. Members holding shares in electronic form are hereby informed that bank particulars registered with their respective depository participants empanelled with NSDL / CDSL, will be used by the Company for payment of dividend. To avoid the delay in receiving the dividend, Members are requested to update their KYC details with their DPs.

#### CONTACT DETAILS

<b>Company</b>	<b>Address:</b> Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, 382110, Gujarat <b>Tel No.</b> +91 9913562852 <b>Email:</b> <a href="mailto:compliance@sotacpharma.com">compliance@sotacpharma.com</a> <b>Web:</b> <a href="http://www.sotacpharma.com">www.sotacpharma.com</a>
<b>Registrar and Transfer Agent</b>	<b>Kfin Technologies Limited</b> Selenium Tower-B, Plot No. 31-32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana-500032 <b>E-mail:</b> <a href="mailto:einward.ris@kfintech.com">einward.ris@kfintech.com</a> <b>Website:</b> <a href="http://www.kfintech.com">www.kfintech.com</a> <b>Tel no.:</b> +91 40 6716 2222
<b>e-Voting Agency &amp; VC / OAVM</b>	<b>Email:</b> <a href="mailto:evoting@nsdl.com">evoting@nsdl.com</a> NSDL help desk 1800-222-990
<b>Scrutinizer</b>	<b>M/S. SCS and Co. LLP</b> <b>Ms. Anjali Sangtani (Membership No. 41942; CP No. 23630)</b> <b>Email:</b> <a href="mailto:scsandcollp@gmail.com">scsandcollp@gmail.com</a> ; <b>Mo. No.:</b> 079-40051702

## EXPLANATORY STATEMENT

*(Pursuant to Section 102 (1) of the Companies Act 2013 and Secretarial Standard II on General Meetings)*

### ITEM NO. 04

**To ratify the remuneration payable to M/s. Suthar Haresh & Associates, Cost Accountants (FRN.: 002124) Cost Auditor of the Company for the Financial Year ended on March 31, 2026: Ordinary Resolution:**

Members may note that as per Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014, your Company is required to maintain cost records and appoint a Cost Auditor to have the cost records audited on annual basis.

The Board of Directors at its meeting held on August 30, 2025, upon the recommendation of the Audit Committee, approved the appointment of M/s. Suthar Haresh & Associates, Cost Accountants (Firm Registration No.: 002124), Ahmedabad, to conduct the audit of the Cost records of the Company for the Financial Year ending on March 31, 2026 at a remuneration of ₹ 50,000/- (Rupees Fifty Thousand Only) plus applicable taxes and reimbursement of out of pocket expenses. In terms of the provisions of Section 148 of the Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014 (as amended or re-enacted from time to time) the remuneration as mentioned above, payable to the Cost Auditors, is required to be ratified by the Members of the Company.

The Cost Auditors have furnished a certificate regarding their eligibility & consent for appointment as Cost Auditors of the Company. They have vast experience in the field of cost audit and have conducted the audit of the cost records of the Company for previous years under the provisions of the Act.

The Board recommends the resolution set out under Item No. 04 for the approval of the Members by way of passing an Ordinary Resolution.

None of the Directors or Key Managerial Personnel of the Company or their relatives, is, in any way, concerned or interested, financially or otherwise, in the aforesaid resolution.

### ITEM NO.: 05

**Ratification of Remuneration payable to Mr. Sharadkumar Dashrathbhai patel (DIN: 07252252), Chairman and Managing Director of the Company for his remaining term: Special Resolution:**

Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252), aged 45 years, is the Promoter, Chairman and Managing Director of the Company, his designation changed from Executive Director to Chairman and Managing Director of the company for a period of 5 years w.e.f. December 12, 2022 in the Extra ordinary general meeting held on December 19, 2022. On the recommendation of the Nomination and Remuneration Committee of the Company, the Board, in its meeting held on August 30, 2025, has considered Ratification of Remuneration payable up to Rs. 2.50 Lakh per month with such increments as may be decided by the Board from time to time to be paid to Mr. Sharadkumar Dashrathbhai Patel, for his remaining tenure as Chairman and Managing Director. The other terms and conditions of his appointment, as approved by the Shareholders vide their resolution dated December 19, 2022 shall remain unchanged.

The Nomination and Remuneration Committee has noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, In the event of absence or inadequacy of profits in any financial year, the remuneration payable to Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252) shall be governed by Schedule V, read with other applicable provisions of the Companies Act, 2013, including any statutory modification(s) or re-enactment(s) thereof.

Pursuant to Sections 196, 197, 198, 203 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and other applicable Regulations of SEBI (LODR) Regulations, 2015, the remuneration payable to Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252) as Chairman and Managing Director is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

#### General Information

**Nature of Industry:** The Company is manufacturing a wide range of pharmaceutical products such as tablets (general & beta-lactum), capsules (general & beta-lactum), oral liquid, dry syrup and external preparations.

**Date of commencement of commercial production:** The Commercial Production has been commenced since incorporation of the Company.

**In case of new companies, expected date of commencement of activities as per project approved by financial Institutions appearing in the prospectus:** Not Applicable

Financial performance based on given indicators:

#### Financial performance based on given indicators:

(Amount in Lakhs)

Particulars	Standalone-Year Ended		Consolidated-Year Ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
Revenue From Operations	6,238.42	6,710.50	9,698.65	10,383.05
Other Income	237.50	131.87	389.68	48.62
Total Income	6,475.92	6,842.37	10,088.33	10,431.67
Less: Total Expenses before Depreciation, Finance Cost and Tax	5470.36	5691.03	8334.86	9,531.51
Profit before Depreciation, Finance Cost and Tax	1005.56	1151.34	1753.47	900.16
Less: Depreciation	247.40	251.11	383.52	310.05
Less: Finance Cost	116.71	101.34	257.95	170.34
Profit Before Prior Period Items and Tax	641.45	798.89	1,112.00	419.77
Prior Period Items	(0.04)	(23.38)	(0.04)	(23.38)
Less: Current Tax	171.47	212.64	171.85	212.64
Less: Deferred tax Liability (Asset)	(7.23)	(8.22)	12.58	(170.39)
Less: Income Tax Prior period	-	(3.79)	-	(3.79)
Profit After Tax	477.17	574.88	927.53	357.93

**Export performance and net foreign exchange:** During the year under review, the Company not having export performance and net foreign exchange expenditure.

**Foreign Investment and collaborations, if any:** No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total Foreign Shareholding was 16,89,600 Equity Shares.

#### Information about the Director:

**Background Details:** Mr. Sharadkumar Dashrathbhai Patel aged 45 years is Promoter-Chairman and Managing Director of the Company. He is having more than 18 years of experience in the field of pharmaceutical industries. He was appointed as a Promoter- Executive Director of the Company since incorporation of the company i.e. December 18, 2015. Subsequently, his designation was re-designated as Chairman & Managing Director for a term of five years with effect from December 12, 2022, pursuant to the approval of the shareholders at the Extraordinary General Meeting held on December 19, 2022. He plays a pivotal role in overseeing and managing the overall operations of the Company, ensuring effective execution of its business strategies. Under his leadership, the Company has been strengthening its market presence while driving sustainable growth.

**Past Remuneration:** In the financial year 2024-25, Mr. Sharadkumar Dashrathbhai Patel was paid total remuneration of Rs. 21 Lakh P.A. as a Managing Director.

**Recognition or awards:** Nil

**Job Profile and his suitability:** Mr. Sharadkumar Dashrathbhai Patel, Promoter-Chairman & Managing Director of the Company, has over 18 years of rich experience in the pharmaceutical industry. He has been associated with the Company since its incorporation on December 18, 2015. He holds an MBA in Operations Management from Indira Gandhi National Open University and a Bachelor's degree in Pharmacy (B. Pharm) from Rajiv Gandhi University of Health Sciences.

**Revised Terms and conditions of Remuneration:** - Basic Salary Upto Rs. 2.50 Lakh per month excluding perquisite for his remaining term.

#### Comparative remuneration profile with respect to Industry, Size of the company, Profile of the position and person:

Taking into consideration the size of the Company, the profile of Mr. Sharadkumar Dashrathbhai Patel, the responsibilities shouldered by him and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

#### Pecuniary relationship directly or indirectly with the company or relationship with managerial personnel:

Mr. Sharadkumar Dashrathbhai Patel has pecuniary relationship to the extent he is promoter-Chairman and Managing Director - Shareholder of the Company.

In compliance with the provisions of Sections 196, 197, 198, 203 and other applicable provisions of the Act, read with Schedule V to the Act, and other applicable Regulations of SEBI (LODR) Regulations, 2015, the terms of Ratification of remuneration specified above are now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for the remaining term of Mr. Sharadkumar Dashrathbhai Patel as a Chairman and Managing Director of the Company until revised further with other terms and conditions remaining unchanged as per the Appointment resolution passed by the shareholders vide their special resolution.

The Board of Directors is of the view that the Ratification of Remuneration payable to Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252), for the existing remaining term as Chairman and Managing Director will be beneficial to the operations of the Company and the same is commensurate with his abilities and experience and accordingly recommends the Special Resolution at Item No. 5 of the accompanying Notice for approval by the Members of the Company.

Except, Mr. Sharadkumar Dashrathbhai Patel (DIN: 07252252) himself, and his relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

**ITEM NO.: 06**

**Ratification of Remuneration payable to Mr. Dineshkumar Babulal Gelot (DIN: 07252132), Whole-time director of the Company for his remaining term- Special Resolution:**

Mr. Dineshkumar Babulal Gelot (DIN: 07252132), aged 42 years, is the Promoter, Whole-time Director of the Company, his designation changed from Executive Director to Whole time Director of the company for a period of 5 years w.e.f. December 12, 2022 in the Extra ordinary general meeting held on December 19, 2022. On the recommendation of the Nomination and Remuneration Committee of the Company, the Board, in its meeting held on August 30, 2025, has considered Ratification of Remuneration payable up to Rs. 2.50 Lakh per month with such increments as may be decided by the Board from time to time to be paid to Mr. Dineshkumar Babulal Gelot, for his remaining tenure as Whole-time Director of the Company. The other terms and conditions of his appointment, as approved by the Shareholders vide their resolution dated December 19, 2022 shall remain unchanged.

The Nomination and Remuneration Committee has noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, in the event of absence or inadequacy of profits in any financial year, the remuneration payable to Mr. Dineshkumar Babulal Gelot (DIN: 07252132) shall be governed by Schedule V, read with other applicable provisions of the Companies Act, 2013, including any statutory modification(s) or re-enactment(s) thereof.

Pursuant to Sections 196, 197, 198, 203 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and other applicable Regulations of SEBI (LODR) Regulations, 2015, remuneration payable to Mr. Dineshkumar Babulal Gelot (DIN: 07252132) as Whole-time director is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

**General Information**

**Nature of Industry:** The Company is manufacturing a wide range of pharmaceutical products such as tablets (general & beta-lactum), capsules (general & beta-lactum), oral liquid, dry syrup and external preparations.

**Date of commencement of commercial production:** The Commercial Production has been commenced since incorporation of the Company.

**In case of new companies, expected date of commencement of activities as per project approved by financial Institutions appearing in the prospectus:** Not Applicable

Financial performance based on given indicators:

**Financial performance based on given indicators:**

(Amount in Lakhs)

Particulars	Standalone-Year Ended		Consolidated-Year Ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
Revenue From Operations	6,238.42	6,710.50	9,698.65	10,383.05
Other Income	237.50	131.87	389.68	48.62
<b>Total Income</b>	<b>6,475.92</b>	<b>6,842.37</b>	<b>10,088.33</b>	<b>10,431.67</b>
Less: Total Expenses before Depreciation, Finance Cost and Tax	5470.36	5691.03	8334.86	9,531.51
Profit before Depreciation, Finance Cost and Tax	1005.56	1151.34	1753.47	900.16
Less: Depreciation	247.40	251.11	383.52	310.05



Less: Finance Cost	116.71	101.34	257.95	170.34
Profit Before Prior Period Items and Tax	641.45	798.89	1,112.00	419.77
<b>Prior Period Items</b>	<b>(0.04)</b>	<b>(23.38)</b>	<b>(0.04)</b>	<b>(23.38)</b>
Less: Current Tax	171.47	212.64	171.85	212.64
Less: Deferred tax Liability (Asset)	(7.23)	(8.22)	12.58	(170.39)
Less: Income Tax Prior period	-	(3.79)	-	(3.79)
<b>Profit After Tax</b>	<b>477.17</b>	<b>574.88</b>	<b>927.53</b>	<b>357.93</b>

**Export performance and net foreign exchange:** During the year under review, the Company not having export performance and net foreign exchange expenditure.

**Foreign Investment and collaborations, if any:** No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total Foreign Shareholding was 16,89,600 Equity Shares.

#### Information about the Director:

**Background Details:** Mr. Dineshkumar Babulal Gelot aged 42 years is Promoter- Whole Time Director of the company. He is having more than 17 years of experience in the field of pharmaceutical industries. He was appointed as a Promoter- Executive Director of the Company since incorporation of the company i.e. December 18, 2015. Subsequently, his designation was re-designated as Whole Time Director for a term of five years with effect from December 12, 2022, pursuant to the approval of the shareholders at the Extraordinary General Meeting held on December 19, 2022. He plays a pivotal role in overseeing and enhancing the company's production operations.

**Past Remuneration:** In the financial year 2024-25, Mr. Dineshkumar Babulal Gelot was paid total remuneration of Rs. 21 Lakh P.A. as a Whole Time Director of the company.

**Recognition or awards:** NIL

**Job Profile and his suitability:** Mr. Dineshkumar Babulal Gelot (DIN: 07252132) is having more than 17 years of experience in the Pharmaceuticals Industries. He was appointed as a Promoter- Executive Director of the Company since incorporation of the company i.e. December 18, 2015. He holds the Degree of Bachelor of Pharmacy from the Hemchandracharya North Gujarat University, Patan, Gujarat. He plays significant role in production department of the company. He is also acting as director in our group companies.

**Revised Terms and conditions of Remuneration:** - Basic Salary Upto Rs. 2.50 Lakh per month excluding perquisite for his remaining term.

#### **Comparative remuneration profile with respect to Industry, Size of the company, Profile of the position and person:**

Taking into consideration the size of the Company, the profile of Mr. Dineshkumar Babulal Gelot, the responsibilities shouldered by him and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

#### **Pecuniary relationship directly or indirectly with the company or relationship with managerial personnel:**

Mr. Dineshkumar Babulal Gelot has pecuniary relationship to the extent he is promoter-Whole time director and Shareholder of the Company of the company.

In compliance with the provisions of Sections 196, 197, 198, 203 and other applicable provisions of the Act, read with Schedule V to the Act, and other applicable Regulations of SEBI (LODR) Regulations, 2015, the terms of Ratification of remuneration specified above are now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for the remaining term of Mr. Dineshkumar Babulal Gelot as a Whole-time director of the Company until revised further with other terms and conditions remaining unchanged as per the Appointment resolution passed by the shareholders vide their special resolution.

The Board of Directors is of the view that the Ratification of Remuneration payable to Mr. Dineshkumar Babulal Gelot (DIN: 07252132), for the existing remaining term as Whole-time director will be beneficial to the operations of the Company and the same is commensurate with his abilities and experience and accordingly recommends the Special Resolution at Item No. 6 of the accompanying Notice for approval by the Members of the Company.

Except, Mr. Dineshkumar Babulal Gelot (DIN: 07252132) himself, and his relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

#### **ITEM NO.: 07**

#### **Revision in of Remuneration payable to Mr. Vishalkumar Patel (DIN: 07252191), Executive Director of the Company: Special Resolution:**

Mr. Vishalkumar Patel (DIN: 07252191), aged 38 years, is the Promoter, Executive Director of the Company. Subsequently, his appointment as Executive Director under schedule V of the act, along with the terms and conditions including remuneration, was approved by the Members through a Special Resolution at the Extraordinary General Meeting held on December 19, 2022. On the recommendation of the Nomination and Remuneration Committee of the Company, and looking to the contributions made by Mr. Vishalkumar Patel the Board, in its meeting held on August 30, 2025 has considered approval of Revised limit of remuneration, i.e. upto Rs. 2.50 Lakh per month with such increments may be decided by the Board from time to time to be paid to Mr. Vishalkumar Patel (DIN: 07252191) for the term of Three (3) years w.e.f. September 01, 2025. The other terms and conditions of his appointment, as approved by the Shareholders vide their special resolution shall remain unchanged.

The Nomination and Remuneration Committee has noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, in the event of loss or inadequacy of profit in any Financial Year, the Remuneration payable to Vishalkumar Patel (DIN: 07252191), shall be governed by Schedule V, read with other applicable provisions of the Companies Act, 2013, including any statutory modification(s) or re-enactment(s) thereof.

Pursuant to Sections 196, 197, 198 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and other applicable Regulations of SEBI (LODR) Regulations, 2015, remuneration payable to Mr. Vishalkumar Patel (DIN: 07252191) as Executive Director is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

#### **General Information**

**Nature of Industry:** The Company is manufacturing a wide range of pharmaceutical products such as tablets (general & beta-lactum), capsules (general & beta-lactum), oral liquid, dry syrup and external preparations.

**Date of commencement of commercial production:** The Commercial Production has been commenced since incorporation of the Company.

**In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:** Not Applicable

Financial performance based on given indicators:

**Financial performance based on given indicators:**

(Amount in Lakhs)

Particulars	Standalone-Year Ended		Consolidated-Year Ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
Revenue From Operations	6,238.42	6,710.50	9,698.65	10,383.05
Other Income	237.50	131.87	389.68	48.62
<b>Total Income</b>	<b>6,475.92</b>	<b>6,842.37</b>	<b>10,088.33</b>	<b>10,431.67</b>
Less: Total Expenses before Depreciation, Finance Cost and Tax	5470.36	5691.03	8334.86	9,531.51
<b>Profit before Depreciation, Finance Cost and Tax</b>	<b>1005.56</b>	<b>1151.34</b>	<b>1753.47</b>	<b>900.16</b>
Less: Depreciation	247.40	251.11	383.52	310.05
Less: Finance Cost	116.71	101.34	257.95	170.34
Profit Before Prior Period Items and Tax	641.45	798.89	1,112.00	419.77
Prior Period Items	(0.04)	(23.38)	(0.04)	(23.38)
Less: Current Tax	171.47	212.64	171.85	212.64
Less: Deferred tax Liability (Asset)	(7.23)	(8.22)	12.58	(170.39)
Less: Income Tax Prior period	-	(3.79)	-	(3.79)
<b>Profit After Tax</b>	<b>477.17</b>	<b>574.88</b>	<b>927.53</b>	<b>357.93</b>

**Export performance and net foreign exchange:** During the year under review, the Company not having export performance and net foreign exchange expenditure.

**Foreign Investment and collaborations, if any:** No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total foreign shareholding was 16,89,600 Equity Shares.

**Information about the Director:**

**Background Details:** Mr. Vishalkumar Devrajbhai Patel aged 38 years is Promoter-Executive Director of the company. He is having more than 11 years of experience in the field of pharmaceutical industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company i.e. December 18, 2015. Thereafter he was re-designated as Executive director under Schedule V of the Act w.e.f. December 12, 2022. He plays significant role in Quality Assurance (QA) department of the company.

**Past Remuneration:** In the financial year 2024-25, Mr. Vishalkumar Devrajbhai Patel was paid total remuneration of Rs. 21 Lakh P.A. as a Director.

**Recognition or awards:** Nil

**Job Profile and his suitability:** Mr. Vishalkumar Devrajbhai Patel aged 38 years is Promoter-Executive Director of the company. He is having more than 11 years of experience in the field of pharmaceutical industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company i.e. December 18, 2015. He plays a significant role in overseeing the Quality Assurance (QA) function of the Company, ensuring compliance with regulatory standards and industry best practices. His active involvement contributes to maintaining high-quality benchmarks across all operations.

**Revised Terms and conditions of Remuneration:** - Basic Salary Upto Rs. 2.50 Lakh per month excluding perquisite for the term of three years w.e.f. September 01, 2025.

**Comparative remuneration profile with respect to Industry, Size of the company, Profile of the position and person:**

Taking into consideration the size of the Company, the profile of Mr. Vishalkumar Patel, the responsibilities shouldered by him and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

**Pecuniary relationship directly or indirectly with the company or relationship with managerial personnel:**

Mr. Vishalkumar Devrajbhai Patel has pecuniary relationship to the extent he is promoter-Executive director, shareholder of the company.

In compliance with the provisions of Sections 196, 197, 198, and other applicable provisions of the Act, read with Schedule V to the Act, and other applicable Regulations of SEBI (LODR) Regulations, 2015, the terms of revised remuneration specified above are now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for the term of three years for Mr. Vishalkumar Devrajbhai Patel as an Executive director of the Company until revised further with other terms and conditions remaining unchanged as per the appointment resolution passed by the shareholders vide their special resolution.

The Board of Directors is of the view that the revision in Remuneration payable to Mr. Vishalkumar Patel (DIN: 07252191) for the term of three years as Executive director will be beneficial to the operations of the Company and the same is commensurate with his abilities and experience and accordingly recommends the Special Resolution at Item No. 7 of the accompanying Notice for approval by the Members of the Company.

Except Mr. Vishalkumar Patel (DIN: 07252191) himself, and his relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

**ITEM NO.: 08**

**Revision in Remuneration payable to Mr. Chetankumar Bachubhai Patel (DIN: 07252116), Executive Director of the Company- Special Resolution:**

Mr. Chetankumar Bachubhai Patel (DIN: 07252116) aged 46 years, is the Promoter, Executive Director of the Company. Subsequently, his appointment as Executive Director under schedule V of the act, along with the terms and conditions including remuneration, was approved by the Members through a Special Resolution at the Extraordinary General Meeting held on December 19, 2022. On the recommendation of the Nomination and Remuneration Committee of the Company, and looking to the contributions made by Mr. Chetankumar Bachubhai Patel the Board, in its meeting held on August 30, 2025 has considered approval of Revised limit of remuneration, i.e. upto Rs. 2.50 Lakh per month with such increments may be decided by the Board from time to time to be paid to Mr. Chetankumar Bachubhai Patel (DIN: 07252116) for the term of Three (3) years w.e.f. September 01, 2025. The other terms and conditions of his appointment, as approved by the Shareholders vide their special resolution shall remain unchanged.

The Nomination and Remuneration Committee has noted that the Company has not made any default in repayment of its dues to Banks or Financial Institutions.

Further, in the event of loss or inadequacy of profit in any Financial Year, the Remuneration payable to Mr. Chetankumar Bachubhai Patel (DIN: 07252116), shall be governed by Schedule V, read with other applicable provisions of the Companies Act, 2013, including any statutory modification(s) or re-enactment(s) thereof.

Pursuant to Sections 196, 197, 198, and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and other applicable Regulations of SEBI (LODR) Regulations, 2015, remuneration payable to Mr. Chetankumar Bachubhai Patel (DIN: 07252116) as Executive Director is now being placed before the Members for their approval by way of Special Resolution.

The relevant disclosures in terms of Schedule V to the Companies Act, 2013 is given hereunder;

#### General Information

**Nature of Industry:** The Company is manufacturing a wide range of pharmaceutical products such as tablets (general & beta-lactum), capsules (general & beta-lactum), oral liquid, dry syrup and external preparations.

**Date of commencement of commercial production:** The Commercial Production has been commenced since incorporation of the Company.

**In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:** Not Applicable

Financial performance based on given indicators:

**Financial performance based on given indicators:**

(Amount in Lakhs)

Particulars	Standalone-Year Ended		Consolidated-Year Ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
Revenue From Operations	6,238.42	6,710.50	9,698.65	10,383.05
Other Income	237.50	131.87	389.68	48.62
<b>Total Income</b>	<b>6,475.92</b>	<b>6,842.37</b>	<b>10,088.33</b>	<b>10,431.67</b>
Less: Total Expenses before Depreciation, Finance Cost and Tax	5470.36	5691.03	8334.86	9,531.51
Profit before Depreciation, Finance Cost and Tax	1005.56	1151.34	1753.47	900.16
Less: Depreciation	247.40	251.11	383.52	310.05
Less: Finance Cost	116.71	101.34	257.95	170.34
<b>Profit Before Prior Period Items and Tax</b>	<b>641.45</b>	<b>798.89</b>	<b>1,112.00</b>	<b>419.77</b>
Prior Period Items	(0.04)	(23.38)	(0.04)	(23.38)
Less: Current Tax	171.47	212.64	171.85	212.64
Less: Deferred tax Liability (Asset)	(7.23)	(8.22)	12.58	(170.39)
Less: Income Tax Prior period	-	(3.79)	-	(3.79)
<b>Profit After Tax</b>	<b>477.17</b>	<b>574.88</b>	<b>927.53</b>	<b>357.93</b>

**Export performance and net foreign exchange:** During the year under review, the Company not having export performance and net foreign exchange expenditure.

**Foreign Investment and collaborations, if any:** No collaborations have been made by the Company with any of foreign entity. Further, as at March 31, 2025 total foreign shareholding was 16,89,600 Equity Shares.

#### Information about the Director:

**Background Details:** Mr. Chetankumar Bachubhai Patel aged 46 years is Promoter-Executive Director of the company. He is having more than 18 years of experience in the field of pharmaceutical industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company i.e. December 18, 2015. Thereafter he was re-designated as Executive director under Schedule V of the Act. He plays significant role in Quality Checking (QC) department of the company.

**Past Remuneration:** In the financial year 2024-25, Mr. Chetankumar Bachubhai Patel was paid total remuneration of Rs. 21 Lakh P.A. as a Director

**Recognition or awards:** Nil

**Job Profile and his suitability:** Mr. Chetankumar Bachubhai Patel aged 46 years is Promoter-Executive Director of the company. He is having more than 18 years of experience in the field of pharmaceutical industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company i.e. December 18, 2015. He plays a significant role in overseeing the Quality Checking function of the Company, ensuring adherence to established quality standards and procedures. His active involvement contributes to delivering consistent and reliable products across all operations.

**Revised Terms and conditions of Remuneration:** - Basic Salary Upto Rs. 2.50 Lakh per month excluding perquisite for the term of three years w.e.f. September 01, 2025.

**Comparative remuneration profile with respect to Industry, Size of the company, Profile of the position and person:**

Taking into consideration the size of the Company, the profile of Mr. Chetankumar Bachubhai Patel, the responsibilities shouldered by him and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level incumbents, in other companies.

**Pecuniary relationship directly or indirectly with the company or relationship with managerial personnel:**

Mr. Chetankumar Bachubhai Patel has pecuniary relationship to the extent he is promoter-Executive director, shareholder of the company.

In compliance with the provisions of Sections 196, 197, 198, and other applicable provisions of the Act, read with Schedule V to the Act, and other applicable Regulations of SEBI (LODR) Regulations, 2015, the terms of revised remuneration specified above are now being placed before the Members for their approval. Further, remuneration proposed above shall be valid for the term of three years for Mr. Chetankumar Bachubhai Patel as an Executive director of the Company until revised further with other terms and conditions remaining unchanged as per the appointment resolution passed by the shareholders vide their special resolution

The Board of Directors is of the view that the revision in Remuneration payable to Mr. Chetankumar Bachubhai Patel (DIN: 07252116) for the term of three years as Executive director will be beneficial to the operations of the Company and the same is commensurate with his abilities and experience and accordingly recommends the Special Resolution at Item No. 8 of the accompanying Notice for approval by the Members of the Company.

Except Mr. Chetankumar Bachubhai Patel (DIN: 07252116) himself, and his relatives to the extent of their shareholding in the Company, none of the Directors or Key Managerial Personnel of the Company including their relatives is interested or concerned in the Resolution.

The statement of additional information required to be disclosed as per Regulation 36(3) of SEBI (LODR) Regulations, 2015 and Secretarial Standard II issued by ICSI is attached at the end of this Explanatory Statement and must be read as the part of this Notice.

**Item No. 09**

**To approve the appointment of Ms. Dimpalben Dhebarbhai Patel (DIN: 11122579) as a Non-Executive Independent Director of the Company for a period of 5 (five) years- Special Resolution:**

Pursuant to the provisions of Section 161 of the Companies Act, 2013(the 'Act'), the Board of Directors of the Company based on the recommendation of the Nomination and Remuneration Committee, appointed Ms. Dimpalben Dhebarbhai Patel (DIN: 11122579) as an Additional Director in the capacity of a Non-Executive Independent Director with effect from May 24, 2025 (date of approval of valid Director Identification Number), at its meeting held on May 22, 2025, for a first term of 5 (five) consecutive years, subject to the approval of Members at the ensuing Annual general meeting of the Company.



The Company has received a Notice under Section 160 of the Act from a Member in writing proposing the candidature of Ms. Dimpalben Dhebarbhai Patel for appointment as a Non-Executive Independent Director of the Company. Ms. Dimpalben Dhebarbhai Patel has given a declaration to the Board that she meets the criteria of Independence as provided under Section 149(6) of the Act.

In the opinion of the Board, Ms. Dimpalben Dhebarbhai Patel fulfils the conditions specified in the Act, Rules made thereunder and Listing Regulations for appointment as an Independent Director and she is independent of management. The Board recommends her appointment as a Non-Executive Independent Director for five (5) consecutive years with effect from May 24, 2025.

Further, Ms. Dimpalben Dhebarbhai Patel has confirmed that she is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact her ability to discharge her duties as an Independent Director of the Company. Ms. Dimpalben Dhebarbhai Patel has also confirmed that she is not debarred from holding the office of a director by virtue of any Order passed by SEBI or any such authority. She is not disqualified from being appointed as a Director in terms of Section 164 of the Act. Further, she has confirmed that she is in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, with respect to his registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs ('IICA').

A copy of the draft letter for the appointment of Ms. Dimpalben Dhebarbhai Patel as a Non-Executive Independent Director setting out the terms and conditions is available for inspection without any fee by the members at the Company's registered office during normal business hours on working days up to Monday, September 29, 2025. The resolution seeks the approval of members for the appointment of Ms. Dimpalben Dhebarbhai Patel as a Non-Executive Independent Director of the Company from May 24, 2025 to May 23, 2030 (both days inclusive) pursuant to Sections 149, 152 and other applicable provisions of the Act and the Rules made thereunder (including any statutory modification(s) or re-enactment(s) thereof) and she shall not be liable to retire by rotation.

The profile and specific areas of expertise of Ms. Dimpalben Dhebarbhai Patel and other relevant information as required under SEBI LODR Regulations and SS-2 is mentioned hereunder.

Ms. Dimpalben Dhebarbhai Patel holds a Master's Degree in Commerce (M. Com) and a Bachelor's Degree in Education (B.Ed.). She is presently serving as a Teacher-cum-Accountant at Sakar English School. With her academic background and professional experience, she brings strong expertise in the field of Accounts. She contributes a broad range of skills and valuable insights in accounting and related areas.

In compliance with the provisions of Section 149 read with Schedule IV to the Act, the approval of the Members is sought for the appointment of Ms. Dimpalben Dhebarbhai Patel as a Non-Executive Independent Director of the Company, as a special resolution as set in item no. 09.

Relevant document in respect of the said item is available electronically for inspection by the Members from the date of Circulation of the Notice of the AGM. Members seeking to inspect such documents can send an email to [compliance@sotacpharma.com](mailto:compliance@sotacpharma.com).

Except Ms. Dimpalben Dhebarbhai Patel, being appointed Director, none of the other Directors or Key Managerial Personnel or their relatives are, in any way, concerned or interested, financially or otherwise, in the aforesaid resolution.

The Board recommends the Special Resolution as set out at item no. 09 for approval by the Members.

#### Item No. 10

#### **To Approve the Material related party transaction(s) proposed to be entered into by the Company during the FY 2025-26 with Sotac Healthcare Private Limited ("Subsidiary company") - Ordinary Resolution:**

Section 188 of the Companies Act 2013 and the applicable Rules framed thereunder provided that any related party transaction will require prior approval of shareholders through ordinary resolution if the aggregate value of transaction(s) amounts to 10% or more of the turnover of the Company as per last audited financial statements of the Company.

Sotac Healthcare Private Limited is related party with reference to the Company within the meaning of Clause (76) of section 2 of the Companies Act 2013.

The value of proposed aggregate transactions with Sotac Healthcare Private Limited is likely to exceed the said threshold limit during the financial year 2025-26.

Accordingly, transaction(s) entered with Sotac Healthcare Private Limited comes within the meaning of Related Party Transaction(s) in terms of provisions of the Act applicable rules framed thereunder.

Hence, approval of the shareholders is being sought by way of Ordinary Resolution as per our related party transactions policy for the said Related Party Transaction(s) proposed to be entered by our Company with Sotac Healthcare Private Limited in the financial year 2025-26.

Although approval of the shareholders would not be required under the provisions of Section 188 of the Companies Act 2013 and the rules made thereunder and as amended from time to time due to the reason that transactions with related party are in the ordinary course of business and at the arm's length basis the same is being sought as an abundant precautionary measure.

Pursuant to Rule 15 of Companies (Meetings of Board and its Powers) Rules, 2014 as amended till date particulars of the transactions with Sotac Healthcare Private Limited are as follows:

Sr. No.	Particulars	Details
1.	<b>Name of Related Parties</b>	Sotac Healthcare Private Limited
2.	<b>Name of the Director or KMP who is related</b>	Mr. Sharadkumar Dashrathbhai Patel, Mr. Chetankumar Bachubhai Patel, Mr. Dineshkumar Babulal Gelot, and Mr. Vishalkumar Patel are Common Directors of both the company.
3.	<b>Nature of Relationship</b>	Sotac Healthcare Private Limited is Subsidiary company of Sotac Pharmaceuticals Limited and above-mentioned related directors are common directors in both companies.
4.	<b>Monetary Value</b>	The estimated aggregate value of contracts/arrangements value for the matters proposed in the resolution shall not exceed Rs. 25 Crores for FY 2025-26 with Sotac Healthcare Private Limited.
5.	<b>Nature materials terms and particulars of the Contracts/arrangements/</b>	Purchase of Raw Materials, Purchase of Products, Purchase of Packing material, Purchase of Finished goods, Sale of Raw Material and Sale of Products and for any other purchase and sale transactions from time to time and the ability to supply, provision/availing of services. However, such transactions would be in ordinary course of the Company's business and at the arm's length basis.
6.	<b>Any advance paid or received for the contracts/arrangements</b>	As per industry norms customs and usages.
7.	<b>Tenure of contracts/arrangement</b>	F.Y. 2025-26
8.	<b>Any other information relevant or important for the members to take a decision on the proposed resolution.</b>	All relevant information's are mentioned in the Explanatory Statement setting out Material Facts, pursuant to Section 102(1) of the Act, forming part of this Notice

Except Mr. Sharadkumar Dashrathbhai Patel, Mr. Chetankumar Bachubhai Patel, Mr. Dineshkumar Babulal Gelot, and Mr. Vishalkumar Patel and their relatives, none of other Director(s) and Key Managerial Personnel(s) and their relative(s) is/are, in any way, concerned or interested in the said resolution.

*Since, entire Promoters and Promoters' Group may construe as Related Party to this transaction, all entities falling under the definition of Promoters and Promoters' Group of the Company shall abstain from voting for this resolution.*

The Board recommends resolution set out under Item No. 10 for the approval of the Members by way of passing an Ordinary Resolution.

#### Item No. 11

#### **To Approve the Material related party transaction(s) proposed to be entered into by the Company during the FY 2025-26 with Sotac Lifesciences Private Limited ("Subsidiary company") - Ordinary Resolution:**

Section 188 of the Companies Act 2013 and the applicable Rules framed thereunder provided that any related party transaction will require prior approval of shareholders through ordinary resolution if the aggregate value of transaction(s) amounts to 10% or more of the turnover of the Company as per last audited financial statements of the Company.

Sotac Lifesciences Private Limited is related party with reference to the Company within the meaning of Clause (76) of section 2 of the Companies Act 2013.

The value of proposed aggregate transactions with Sotac Lifesciences Private Limited is likely to exceed the said threshold limit during the financial year 2025-26.

Accordingly, transaction(s) entered with Sotac Lifesciences Private Limited comes within the meaning of Related Party Transaction(s) in terms of provisions of the Act applicable rules framed thereunder.

Hence, approval of the shareholders is being sought by way of Ordinary Resolution as per our related party transactions policy for the said Related Party Transaction(s) proposed to be entered by our Company with Sotac Lifesciences Private Limited in the financial year 2025-26.

Although approval of the shareholders would not be required under the provisions of Section 188 of the Companies Act 2013 and the rules made thereunder and as amended from time to time due to the reason that transactions with related party are in the ordinary course of business and at the arm's length basis the same is being sought as an abundant precautionary measure.

Pursuant to Rule 15 of Companies (Meetings of Board and its Powers) Rules, 2014 as amended till date particulars of the transactions with Sotac Lifesciences Private Limited are as follows:

Sr. No.	Particulars	Details
1.	<b>Name of Related Parties</b>	Sotac Lifesciences Private Limited
2.	<b>Name of the Director or KMP who is related</b>	Mr. Sharadkumar Dashrathbhai Patel and Mr. Vishalkumar Patel are Common Directors of both the company.
3.	<b>Nature of Relationship</b>	Sotac Healthcare Private Limited is Subsidiary company of Sotac Pharmaceuticals Limited and above-mentioned related directors are common directors in both companies.
4.	<b>Monetary Value</b>	The estimated aggregate value of contracts/arrangements value for the matters proposed in the resolution shall not exceed Rs. 25 Crores for FY 2025-26 with Sotac Lifesciences Private Limited.

5.	<b>Nature materials terms and particulars of the Contracts/arrangements/</b>	Purchase of Raw Materials, Purchase of Products, Purchase of Packing material, Purchase of Finished goods, Sale of Raw Material and Sale of Products and for any other purchase and sale transactions from time to time and the ability to supply, provision/availing of services. However, such transactions would be in ordinary course of the Company's business and at the arm's length basis.
6.	<b>Any advance paid or received for the contracts/arrangements</b>	As per industry norms customs and usages.
7.	<b>Tenure of contracts/arrangement</b>	F.Y. 2025-26
8.	<b>Any other information relevant or important for the members to take a decision on the proposed resolution.</b>	All relevant information's are mentioned in the Explanatory Statement setting out Material Facts, pursuant to Section 102(1) of the Act, forming part of this Notice

Except Mr. Sharadkumar Dashrathbhai Patel, and Mr. Vishalkumar Patel and their relatives, none of other Director(s) and Key Managerial Personnel(s) and their relative(s) is/are, in any way, concerned or interested in the said resolution.

*Since, entire Promoters and Promoters' Group may construe as Related Party to this transaction, all entities falling under the definition of Promoters and Promoters' Group of the Company shall abstain from voting for this resolution.*

The Board recommends resolution set out under Item No. 11 for the approval of the Members by way of passing an Ordinary Resolution.

#### Item No. 12

#### **To Approve the Material related party transaction(s) proposed to be entered into by the Company during the FY 2025-26 with Sotac Research Private Limited ("Wholly Owned Subsidiary company") - Ordinary Resolution:**

Section 188 of the Companies Act 2013 and the applicable Rules framed thereunder provided that any related party transaction will require prior approval of shareholders through ordinary resolution if the aggregate value of transaction(s) amounts to 10% or more of the annual turnover of the Company as per last audited financial statements of the Company.

Sotac Research Private Limited is related party with reference to the Company within the meaning of Clause (76) of section 2 of the Companies Act 2013.

The value of proposed aggregate transactions with Sotac Research Private Limited is likely to exceed the said threshold limit during the financial year 2025-26.

Accordingly, transaction(s) entered with Sotac Research Private Limited comes within the meaning of Related Party Transaction(s) in terms of provisions of the Act applicable rules framed thereunder.

Hence, approval of the shareholders is being sought by way of Ordinary Resolution as per our related party transactions policy for the said Related Party Transaction(s) proposed to be entered by our Company with Sotac Research Private Limited in the financial year 2025-26.

Although approval of the shareholders would not be required under the provisions of Section 188 of the Companies Act 2013 and the rules made thereunder and as amended from time to time due to the reason that transactions with related party are in the ordinary course of business and at the arm's length basis the same is being sought as an abundant precautionary measure.

Pursuant to Rule 15 of Companies (Meetings of Board and its Powers) Rules, 2014 as amended till date particulars of the transactions with Sotac Research Private Limited are as follows:

Sr. No.	Particulars	Details
1.	<b>Name of Related Parties</b>	Sotac Research Private Limited
2.	<b>Name of the Director or KMP who is related</b>	Mr. Sharadkumar Dashrathbhai Patel, Mr. Dineshkumar Babulal Gelot and Mr. Chetankumar Bachubhai Patel are Common Directors of both the Company.
3.	<b>Nature of Relationship</b>	Sotac Research Private Limited is Wholly owned Subsidiary company of Sotac Pharmaceuticals Limited and above-mentioned related directors are common directors in both companies.
4.	<b>Monetary Value</b>	The estimated aggregate value of contracts/arrangements value for the matters proposed in the resolution shall not exceed Rs. 25 Crores for FY 2025-26 with Sotac Research Private Limited.
5.	<b>Nature materials terms and particulars of the Contracts/arrangements/</b>	Purchase of Raw Materials, Purchase of Products, Purchase of Packing material, Purchase of Finished goods, Sale of Raw Material and Sale of Products and for any other purchase and sale transactions from time to time and the ability to supply, provision/availing of services. However, such transactions would be in ordinary course of the Company's business and at the arm's length basis.
6.	<b>Any advance paid or received for the contracts/arrangements</b>	As per industry norms customs and usages.
7.	<b>Tenure of contracts/arrangement</b>	F.Y. 2025-26
8.	<b>Any other information relevant or important for the members to take a decision on the proposed resolution.</b>	All relevant information's are mentioned in the Explanatory Statement setting out Material Facts, pursuant to Section 102(1) of the Act, forming part of this Notice

Except Mr. Sharadkumar Dashrathbhai Patel, Mr. Dineshkumar Babulal Gelot, Mr. Chetankumar Bachubhai Patel and their relatives, none of other Director(s) and Key Managerial Personnel(s) and their relative(s) is/are, in any way, concerned or interested in the said resolution.

*Since, entire Promoters and Promoters' Group may construe as Related Party to this transaction, all entities falling under the definition of Promoters and Promoters' Group of the Company shall abstain from voting for this resolution.*

The Board recommends resolution set out under Item No. 12 for the approval of the Members by way of passing an Ordinary Resolution.

### Annexure to Notice of 10th Annual General Meeting

Disclosure under Regulation 36 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards-II issued by ICSI for Item no. 02, 05, 06, 07, 08 & 09:

Name	Mr. Sharadkumar Dashrathbhai patel	Mr. Dineshkumar Babulal Gelot
<b>DIN</b>	07252252	07252132
<b>Date of Birth</b>	September 05, 1979	May 10, 1983
<b>Age</b>	45 years	42 years
<b>Nationality</b>	Indian	Indian
<b>Qualification</b>	Holds the Degree of the Master of Business Administration (MBA) in the Operation Management from the Indira Gandhi National Open University and the Degree of Bachelor of Pharmacy (B. Pharm) from the Rajiv Gandhi University of Health Sciences.	Holds the Degree of Bachelor of Pharmacy from the Hemchandracharya North Gujarat University, Patan, Gujarat.
<b>Date of Original Appointment</b>	December 18, 2015	December 18, 2015
<b>Date of Appointment in current terms</b>	December 12, 2022	December 12, 2022
<b>Experience – Expertise in specific functional areas – Job profile and suitability</b>	He is having more than 18 years of experience in the field of pharmaceutical industries. He was appointed as a Promoter- Executive Director of the Company since incorporation of the company i.e. December 18, 2015. He plays key role in overall operations of the company.	He is having more than 17 years of experience in the Pharmaceuticals Industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company. He plays significant role in Quality Assurance (QA) department of the company.
<b>No. of Shares held as on March 31, 2025 including shareholding as a Beneficial Owner</b>	14,31,500 equity shares	14,31,500 equity shares
<b>No. of Board Meetings Attended During the Year</b>	13 Meetings out of 13 Board Meetings	11 Meetings out of 13 Board Meetings
<b>Directorships held in other Companies as on March 31, 2025</b>	<ol style="list-style-type: none"> <li>1. Samyati Stays Private Limited</li> <li>2. Sotac Lifesciences Private Limited</li> <li>3. Sotac Research Private Limited</li> <li>4. Sotac Healthcare Private Limited</li> </ol>	<ol style="list-style-type: none"> <li>1. Sotac Healthcare Private Limited</li> <li>2. Sotac Research Private Limited</li> </ol>
<b>Memberships / Chairmanships* of committees of public companies (as on the date of this report)</b>	Membership: 1	Membership: Nil
<b>Inter-se<sup>^</sup> Relationship with other Directors.</b>	Not related to any Directors & KMP of the Company.	Not related to any Directors & KMP of the Company.
<b>Terms &amp; Conditions of appointment or re-appointment</b>	Holds office for the period of 5 (Five) years w.e.f. December 12, 2022, liable to retire by rotation.	Holds office for the period of 5 (Five) years w.e.f. December 12, 2022, liable to retire by rotation.
<b>Remuneration Last Drawn</b>	Rs. 21 Lakhs per annum	Rs. 21 Lakhs per annum



<b>Remuneration sought to be paid</b>	Up to Rs. 2.50 Lakhs per month	Up to Rs. 2.50 Lakhs per month
<b>Listed entities from which the person has resigned in the past three years.</b>	-	-
<b>Information as required pursuant to NSE Circular No. L1ST/COMP/14/2018- 19 dated June 20, 2018</b>	Mr. Sharadkumar Dashrathbhai patel is not debarred from holding the office of director pursuant to any SEBI order or any other such authority.	Mr. Dineshkumar Babulal Gelot is not debarred from holding the office of director pursuant to any SEBI order or any other such authority.

<b>Name</b>	<b>Mr. Vishalkumar Patel</b>	<b>Mr. Chetankumar Bachubhai Patel</b>	<b>Ms. Dimpalben Dhebarbhai Patel</b>
<b>DIN</b>	07252191	07252116	11122579
<b>Date of Birth</b>	April 04, 1987	March 28, 1979	March 10, 1979
<b>Age</b>	38 years	46 years	46 years
<b>Nationality</b>	Indian	Indian	Indian
<b>Qualification</b>	Holds the Degree of the Master of Pharmacy in Quality Assurance from the Gujarat Technological University and the Degree of Pharmacist from the State Pharmacy Council, Gujarat.	Holds the Degree of Master of Science (Technology) from the University of Mumbai-Institute of Chemical Technology and Degree of Bachelor of Pharmacy from the K. B Institute of Pharmaceuticals Education & Research, Gujarat University.	Holds the Degree of Master's in Commerce (M. Com) and a Bachelor's Degree in Education (B.Ed.). She is presently serving as a teacher-cum-Accountant at Sakar English School.
<b>Date of Original Appointment</b>	December 18, 2015	December 18, 2015	May 24, 2025
<b>Date of Appointment in current terms</b>	December 18, 2015	December 18, 2015	May 24, 2025
<b>Experience – Expertise in specific functional areas – Job profile and suitability</b>	He is having more than 10 years of experience in the field of pharmaceutical industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company i.e. December 18, 2015. He plays significant role in Quality Assurance (QA) department of the company.	He is having more than 18 years of experience in the field of pharmaceutical industries. He was appointed as Promoter-Executive Director of the company since incorporation of the company i.e. December 18, 2015. He plays significant role in Quality Checking (QC) department of the company.	She is having 13 years of experience in the field of Accounts. She was appointed as Additional (Non-Executive Independent Director) of the company from May 24, 2025 subject to approval of members at this 10 <sup>th</sup> Annual General meeting of the company.
<b>No. of Shares held as on March 31, 2025 including shareholding as a Beneficial Owner</b>	14,31,500 equity shares	10,69,250 equity shares	-
<b>No. of Board Meetings Attended During the Year</b>	13 Meetings out of 13 Board Meetings	13 Meetings out of 13 Board Meetings	N.A.
<b>Directorships held in other Companies as on March 31, 2025</b>	<ol style="list-style-type: none"> <li>1. Sotac Lifesciences Private Limited</li> <li>2. Sotac Healthcare Private</li> </ol>	<ol style="list-style-type: none"> <li>1. Sotac Healthcare Private Limited</li> <li>2. Sotac Research Private</li> </ol>	-

	Limited	Limited	
<b>Memberships / Chairmanships* of committees of public companies (as on the date of this report)</b>	-	-	Membership: 2
<b>Inter-se^ Relationship with other Directors.</b>	Not related to any Directors & KMP of the Company.	Not related to any Directors & KMP of the Company.	Not related to any Directors & KMP of the Company.
<b>Terms &amp; Conditions of appointment or re-appointment</b>	liable to retire by rotation.	liable to retire by rotation.	Holds office for the period of 5 (Five) years w.e.f. May 24, 2025, not liable to retire by rotation (subject to approval of the members in this 10 <sup>th</sup> AGM)
<b>Remuneration Last Drawn</b>	Rs. 21 Lakhs per annum	Rs. 21 Lakhs per annum	Not Applicable
<b>Remuneration sought to be paid</b>	Up to Rs. 2.50 Lakhs per month	Up to Rs. 2.50 Lakhs per month	Not Applicable
<b>Listed entities from which the person has resigned in the past three years.</b>	-	-	-
<b>Information as required pursuant to NSE Circular No. L1ST/COMP/14/2018- 19 dated June 20, 2018</b>	Mr. Vishalkumar Patel is not debarred from holding the office of director pursuant to any SEBI order or any other such authority.	Mr. Chetankumar Bachubhai Patel is not debarred from holding the office of director pursuant to any SEBI order or any other such authority.	Ms. Dimpalben Dhebarbhai Patel is not debarred from holding the office of director pursuant to any SEBI order or any other such authority.

\*Includes only Audit Committee and Stakeholders' Relationship Committee.

^In accordance with SEBI (ICDR) Regulations, 2018 and the Companies Act, 2013.